Search for: "Par Pharmaceutical, Inc." Results 41 - 60 of 172
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
18 Oct 2012, 1:00 am by Courtenay Brinckerhoff
Par Pharmaceutical Inc., the Federal Circuit upheld the district court’s determination that the patents at issue were not invalid as obvious and were infringed by the subject Abbreviated New Drug Applications (ANDAs). [read post]
18 Oct 2008, 8:19 am
In the Hatch-Waxman area, Pozen, Inc. announced Par Pharmaceutical Inc. has filed an application with the Food and Drug Administration [FDA] to make a generic version of Treximet, a migraine treatment Pozen developed with GlaxoSmithKline PLC, and shares of Pozen shed nearly 28 percent of their value on 17 Oct. 08 [read post]
29 Nov 2015, 9:54 pm by Patent Docs
• Defendants: Amneal Pharmaceuticals LLC; Amneal Pharmaceuticals of New York LLC; Par Pharmaceutical, Inc. [read post]
9 Sep 2011, 6:56 am by Ed Wallis
Par Pharmaceutical Cos., 06-6131, US District Court, Northern District of Illinois (Chicago). [read post]
3 Jul 2014, 9:40 pm by Patent Docs
Par Pharmaceutical Inc. 1:14-cv-00789; filed June 20, 2014 in the District Court of Delaware Infringement of U.S. [read post]
26 Jan 2016, 11:23 am by Lawrence B. Ebert
**As one small footnote, Ampyra is not a disease-modifying treatment for MS, in contrast to Copaxone or Tecfidera.link to BNA report: http://www.bna.com/acorda-par-settle-n57982066522/ [read post]
15 Sep 2009, 9:55 pm
By Suresh Pillai -- Purdue Files Appeal in Ultram ® Suit against Par Purdue Pharma Products Inc. has filed an appeal with the U.S. [read post]
16 Sep 2021, 12:57 pm by Simmons Hanly Conroy
Suffolk and Nassau Counties will each receive $13.85 million in combined settlements from Endo and its subsidiary Par Pharmaceutical, Inc. [read post]
19 Apr 2009, 7:13 pm
Par Pharmaceutical, Inc. v. [read post]
28 Oct 2011, 7:10 am
by Kyle Deighan On October 14, Par Pharmaceutical, Inc. [read post]
20 May 2015, 1:00 am by Paul Caron
Wall Street Journal, Rules Fail To Rein In Tax-Driven Takeovers: Endo International PLC agreed to buy rival drug maker Par Pharmaceutical Holdings Inc. for $8 billion, the latest in a string of cross-border mergers steering tax revenue away from the U.S., despite Washington’s efforts. [read post]
31 Jul 2020, 4:48 am
Complete Business Solutions Group Inc. d/b/a/ Par Funding et al. [read post]
28 Oct 2007, 9:50 pm
Par Pharmaceutical Inc. et al. 1:07-cv-00666; filed October 24, 2007 in the... [read post]
13 May 2007, 5:18 pm
Par Pharmaceuticals Inc. et. al.1:07-cv-00255; filed May 9, 2007 in the District... [read post]
19 Oct 2012, 6:13 pm by John W. Arden
The majority of the assets in these 18 markets would be divested to Par Pharmaceutical, Inc. [read post]
18 Oct 2009, 5:42 pm
  Judge Brown found that the patent in question, US Patent No. 5,565,473, was valid and enforceable, and [...]...FTC Sues Regarding AndroGel Patent Settlement The Federal Trade Commission has filed a complaint in federal district court challenging agreements in which Solvay Pharmaceuticals, Inc. paid generic drug makers Watson Pharmaceuticals, Inc. and Par Pharmaceutical Companies, Inc. to delay generic competition to… [read post]
10 Oct 2011, 10:00 am by Lucas A. Ferrara, Esq.
Teva, Ranbaxy Pharmaceuticals, Inc., Mylan Pharmaceutical Inc., and Barr Laboratories, Inc. - which Teva now owns - all have taken steps toward entering the market, and all are eligible to seek a 180-day marketing exclusivity provided under federal law. [read post]
6 Mar 2009, 7:03 am
The complaint also names generic pharmaceutical companies Watson Pharmaceuticals, Par Pharmaceuticals and Paddock Laboratories. [read post]